Thyroid function during the first year of use of the injectable contraceptive depot medroxyprogesterone acetate

Purpose: The aim of the study was to evaluate thyroid function profile as a possible factor influencing weight and body composition variation in new users of depot medroxyprogesterone acetate (DMPA).Materials and methods: A prospective, non-randomised, comparative study was conducted at the University of Campinas, Brazil. Women aged 18-40years with a body mass index (BMI) less than 30kg/m(2), normal oral glucose tolerance test, no known diseases, and using no medication, who opted to use DMPA were paired by age (1year) and BMI (1kg/m(2)) with women initiating copper intrauterine device (IUD) use. The main outcome measures were thyroid function profile, weight, and body composition, as measured by dual-energy X-ray absorptiometry. We used repeated measures ANOVA to perform comparisons between times and groups.Results: We evaluated 28 DMPA users and 24 IUD users who completed the 12-month follow-up. We observed that FT4 levels were higher at 12months (compared to baseline) in the DMPA group (p<.0001) and that FT4/FT3 ratio had increased in both groups. Additionally, at 12months, total body mass had increased around 2kg and lean mass increased in the DMPA group compared to the IUD group; there was also an increase in weight, BMI, total body mass, and fat mass when compared to baseline.Conclusions: No changes in thyroid function occurred that could explain the weight increase observed in DMPA users.242102108CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESPSem informaçãoSem informaçã